Loading...
•
Dec 31, 2022
Innoviva Q4 2022 Earnings Report
Reported financial results for the fourth quarter, highlighting company progress through acquisitions and advancements in its infectious disease and hospital business.
Key Takeaways
Innoviva reported solid results in its diversified core royalty business, with RELVAR®/BREO® ELLIPTA® global net sales decreasing due to unfavorable adjustments in the U.S., offset by stable volume trends. GIAPREZA® and XERAVA® had their strongest quarter ever, and the company is advancing its strategy of building a best-in-class hospital and infectious disease business.
Core royalty business remained solid despite some sales decreases.
GIAPREZA® and XERAVA® achieved their strongest quarter to date.
FDA accepted SUL-DUR NDA with Priority Review.
Enrollment in the Phase 3 registrational trial of zoliflodacin remains on track, with study completion anticipated in 2023.
Forward Guidance
Innoviva is focused on building a best-in-class hospital and infectious disease business and is optimistic about future prospects, maintaining capital discipline and executing a share buyback program.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...